Enterofuryl suspension for oral administration 90 ml
Condition: New product
998 Items
Rating:
Be the first to write a review!
More info
Active ingredients
Nifuroxazide
Release form
Suspension
Composition
5 ml of the suspension contain: Active ingredient: nifuroxazide 200.0 mg Auxiliary substances: sucrose 1000.0 mg, sodium hydroxide 2.0 mg, methyl parahydroxybenzoate 5.0 mg, ethanol 96% 0.05 ml, carbomer 10.5 mg, citric acid 0 , 75mg, banana flavor 10.00mg, water up to 5.0 ml.
Pharmacological effect
Enterofuryl is a broad-spectrum antimicrobial drug that does not have a systemic effect and is used to treat diarrhea of infectious etiology. The composition of the drug Enterofuryl includes the active substance nifuroxazide, a drug of the group of 5-nitrofuran derivatives. The drug has a bactericidal and bacteriostatic effect against most pathogens of acute intestinal infections. The antimicrobial effect of nifuroxazide is dose-dependent: for example, low and medium doses of the drug have a bacteriostatic effect on pathogenic microflora, and high - bactericidal. The bacteriostatic mechanism of action of the drug is associated with inhibition of the activity of the enzyme dehydrogenase, which leads to disruption of the normal course of the synthesis of vital compounds in the cell of a microorganism. Thus, due to the effect of nifuroxazide on the cell of the microorganism, a violation of the respiratory chain, inhibition of the tricarboxylic acid cycle, is observed. In addition, the drug Enterofuryl inhibits the synthesis of proteins in the cell of the microorganism and inhibits other biochemical processes in the bacterial cell. Thus, the cell of the microorganism loses its ability to reproduce.
Pharmacokinetics
After taking the drug inside nifuroksazid almost not absorbed from the gastrointestinal tract, showing its antibacterial action only in the intestinal lumen. Completely excreted in the feces. The rate of excretion depends on both the dose and intestinal motility.
Indications
- diarrhea of bacterial genesis; - chronic lesions of the gastrointestinal tract of bacterial etiology, accompanied by dyspeptic phenomena.
Contraindications
- hypersensitivity to the components of the drug or other nitrofuran derivatives; - fructose intolerance; - glucose-galactose malabsorption syndrome or sucrase and isomaltase deficiency; - up to 1 month old, premature infants (oral suspension).
Use during pregnancy and lactation
Use of the drug Enterofuryl during pregnancy is possible only in cases where the expected benefit of therapy for the mother outweighs the potential risk to the fetus. Enterofuryl is not absorbed from the gastrointestinal tract and does not enter the systemic circulation, but the use of the drug during lactation is possible only under strict indications, and the issue of discontinuing breastfeeding should be decided.
Dosage and administration
It is applied inside. For dosing, a 5 ml dosing spoon with a graduation of 2.5 ml is used. Before use, the suspension should be shaken well. Children 1-6 months: 2.5 ml 2 - 3 times a day (with an interval of 8 to 12 hours ). Children from 7 months to 2 years: 2.5 ml 4 times a day (with an interval of 8 hours). Children from 3 to 7 years: 5 ml 3 times a day (with an interval of 8 hours). Children over 7 years old and adults: 5 ml 3-4 times a day (with an interval of 6-8 hours). Nifuroxazide therapy should not last more than 7 days.
Side effects
Allergic reactions: rash, urticaria, angioedema, anaphylactic shock. On the digestive system: nausea, vomiting.
Overdose
The drug is not absorbed from the gastrointestinal tract and does not enter the systemic circulation. Symptoms of overdose are not known. If the dose is exceeded, gastric lavage and symptomatic treatment are recommended.
Interaction with other drugs
There is no evidence that nifuroxazide interacts with other drugs.
special instructions
In the treatment of diarrhea, simultaneously with therapy with Enterofuryl, it is necessary to conduct rehydration therapy (oral or IV) in accordance with the patient's condition and the intensity of diarrhea. It increases the body's sensitivity to nifuroxazide. If symptoms of hypersensitivity appear (dyspnea, rash, itching), the drug should be discontinued. driving vehicles and driving mechanisms The drug does not affect the psychomotor activity and ability to drive vehicles and work with mechanisms.